clinical trial · NCT05064371
Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan
H. Lundbeck A/S·phase3·completed·n = 160
MigraineEptinezumab
brief summary
This study is an open label extension study, which means that the participants from the Lead-in Study 19140A (NCT04921384) can join this study, if they meet the study Eligibility Criteria, and continue to receive the study drug eptinezumab. The main goal of this study is to investigate long-term safety and tolerability of eptinezumab in Japanese migraine participants.
started
Sep 21, 2021
primary completion
Jun 8, 2024
completion
Jun 8, 2024
last updated
Jan 14, 2026
detailed description
The total study duration from the Baseline Visit to the Safety Follow-up Visit is approximately 68 weeks and includes an Open-Label Treatment Period (60 weeks) and a Safety Follow-up Period (8 weeks).
official title
Interventional, Open-label, Fixed-dose, Long-term Extension Study to Evaluate Safety of Eptinezumab as Preventive Treatment in Patients With Migraine
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol